FRANKFURT -(MarketWatch)- German chemical and pharmaceutical company Bayer AG (BAYN.XE) aims to restructure its diagnostics business, part of the Schering brand it bought in 2006, by selling one section of it and incorporating the other section into another business, according to a report in Friday’s Financial Times Deutschland citing people close to the matter.
Bayer wasn’t immediately available to comment on the report.
The report says Bayer aims to sell its molecular imaging business, which doesn’t have any products on the market but is in a final pre-market stage with florbetaben PET imaging, a tracer used in the diagnosis of Alzheimer’s disease.
Florbetaben is one of Bayer’s most important pipeline products in an advanced stage of development, according to the article.
Bayer has been searching for a buyer for the unit, according to the article, and has already notified about a hundred employees who would be affected by a possible sale.
The other part of the diagnostics business, which encompasses products like MRI contrast agent Magnevist and radiological contrast agent Ultravist, will be fused with another segment in Bayer’s Medical Care division, according to the newspaper, which cites a letter to Bayer employees.
